-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DR-0201 in Follicular Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DR-0201 in Follicular Lymphoma Drug Details: DR-0201 is under development for the treatment of hematologic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Linvoseltamab in Multiple Myeloma (Kahler Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Linvoseltamab in Multiple Myeloma (Kahler Disease) Drug Details: Linvoseltamab (REGN-5458) is under development for the...
-
Analyst Opinions
New![]()
Novel and Experimental – Consumer TrendSights Analysis, 2023
"Novel & Experimental" is one of the 63 sub-trends that GlobalData covers as part of our TrendSights series of Consumer Insight studies. The analysis covers what the trend is, why it is important, who is most influenced by it and how brands and manufacturers can capitalize. The research concludes by identifying where the trend is heading next and how long it will last. Brands are engaging with consumers with unusual flavor combinations. For example, McDonald's India is launching novel non-alcoholic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Linvoseltamab in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Linvoseltamab in Refractory Multiple Myeloma Drug Details: Linvoseltamab (REGN-5458) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LAVA-1223 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LAVA-1223 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: LAVA-1223 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JANX-008 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. JANX-008 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: JANX-008 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imvotamab in Systemic Lupus Erythematosus
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Imvotamab in Systemic Lupus Erythematosus Drug Details: Imvotamab is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imvotamab in Rheumatoid Arthritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Imvotamab in Rheumatoid Arthritis Drug Details: Imvotamab is under development for the treatment of rituximab...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Linvoseltamab in Relapsed Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Linvoseltamab in Relapsed Multiple Myeloma Drug Details: Linvoseltamab (REGN-5458) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JANX-008 in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. JANX-008 in Metastatic Colorectal Cancer Drug Details: JANX-008 is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.